A New Vaccine Platform Could Cut Development Timelines From Months to Weeks
When a new infectious disease begins to spread, any delay has consequences. During the COVID-19 pandemic, vaccines reached the public faster than ever, but even that effort depended on complex supply chains and cold storage that limited access in many parts of the world.
Researchers at the University of Virginia School of Medicine are currently testing a vaccine development platform designed to further shorten this timeline. In a study published in the journal VaccinesThe team describes an approach that aims to move from vaccine design to early production within weeks, while reducing manufacturing costs and facilitating distribution. If the method continues to work as early tests suggest, it could offer a more flexible way to respond to outbreaks, particularly in regions where refrigeration, specialized facilities and funding are scarce.
“Governments and others have said that a new vaccine for a pandemic threat should be able to be made in 100 days, but we believe that with our platform we can make a new vaccine for testing in 3 weeks,” Steven L. Zeichner, lead author of the study, said in a press release.
Rethinking vaccine development
Most vaccines used today rely on weakened pathogens, purified proteins, or, more recently, mRNA. Each approach has proven effective, but each also introduces logistical challenges, ranging from complex manufacturing to strict temperature requirements.
Zeichner’s platform follows a different logic. Rather than delivering genetic instructions directly to human cells, it uses bacteria to produce vaccine material in advance. The strategy is rooted in older vaccine methods but reimagined with modern molecular tools.
The process begins by identifying a fragment of a virus or other pathogen that can trigger protective immunity. This target is then modified to shape the immune system’s response. The synthetic DNA instructions encoding the template are inserted into bacteria, which produce the vaccine material before being inactivated.
Vaccines based on killed bacteria have been around for over a century. The difference is how precisely researchers can shape the immune response. Modern protein design allows researchers to fine-tune immune responses in ways that previous methods could not.
Learn more: Dental floss has the potential to deliver vaccines, replace needles or nasal sprays
Early studies show strong immune responses
In a recent proof-of-concept study, Zeichner and colleagues tested whether the platform could reliably generate vaccines that elicit strong immune responses. In several cases, vaccines produced using the system triggered up to eight times greater immune activity than earlier versions of the same target.
To guide their designs, the team used AlphaFold, an artificial intelligence system that predicts how proteins fold to form three-dimensional shapes. This allowed researchers to assess whether a vaccine candidate would perform as expected before any physical manufacturing began.
By moving much of the trial and error phase to the design phase, the platform could significantly reduce development times. Researchers estimate that a vaccine candidate could be ready for early testing in about three weeks.
Why faster, cheaper vaccines are important during epidemics
Speed is only part of the equation. Since vaccines can be produced using existing bacteria manufacturing facilities, costs could fall well below a dollar per dose. Vaccines should also remain stable at standard refrigerator temperatures, reducing the need for specialized cold chain infrastructure.
These characteristics could be particularly important during global epidemics, when unequal access to vaccines allows diseases to spread and evolve. Limiting these gaps is not only a public health goal, but also a practical one.
The researchers emphasize that the platform remains under development and that any vaccine must undergo extensive testing for safety and effectiveness. Still, the work suggests that responding to new infectious threats may depend less on complex logistics than on how quickly a vaccine can be designed, built and shared.
This article does not offer medical advice and should be used for informational purposes only.
Learn more: Why do viruses like COVID-19 and flu mutate quickly and what does this mean for vaccines?
Article Sources
Our Discovermagazine.com editors use peer-reviewed research and high-quality sources for our articles, and our editors review the articles for scientific accuracy and editorial standards. See the sources used below for this article:
